1233243-49-6

Basic information

• Product Name: (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide
• CAS NO: 1233243-49-6
• Molecular Weight: 166.18
• Mol File: 1233243-49-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide(1233243-49-6)
• EPA Substance Registry System: (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide(1233243-49-6)

Safety Data

• Hazardous Substances Data: 1233243-49-6(Hazardous Substances Data)

Upstream product

• 874-89-5 4-Cyanobenzyl alcohol 

Downstream Products

• 635701-59-6 1-{4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl}-3-azetidine carboxylic acid 
• 635701-88-1 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzaldehyde 
• 635702-24-8 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl alcohol 
• 1377936-30-5 (4-(5-(1-(3,4-dimethylbenzyl)-5-methyl-1H-indol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)methanol 
• 1377936-34-9 4-(5-(1-benzyl-1H-indol-3-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde 
• 1377936-03-2 3-({4-[5-(1-benzyl-1H-indol-3-yl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propanoic acid 
• 1377936-33-8 (4-(5-(1-benzyl-1H-indol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)methanol 
• 1246015-40-6 C₁₇H₂₄N₂O₂ 
• 1218817-72-1 (4-(5-heptyl-1,2,4-oxadiazol-3-yl)phenyl)methanol 

Relevant articles and documents

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

Oxadiazole derivatives as S1P1 receptor agonists

New compounds having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof wherein A is selected from the group consisting of -N-, -O- and -S-; B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein RC represents a hydrogen atom, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; R1 is selected from the group consisting of hydrogen atoms, C1-4 alkyl groups, C1-4 alkoxy groups, C3-4 cycloalkyl groups, and -NRdRe groups wherein Rd and Re are independently selected from hydrogen atoms and C1-4 alkyl groups; R2 and R3 are independently selected from the group consisting of hydrogen atoms and C1-4 alkyl groups; R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, halogen atoms, C1-4 alkyl groups, C1-4 alkoxy groups and C1-4 haloalkyl groups; R6 represents a C1-4 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NRaRb groups, -(CRfRg)n-(CRhRi)x-(CRjRk)y-NRaRb groups, -(CH2)n-NRaRb groups, -O-(CH2)n-NRaRb groups, -(CH2)n-COOH groups, -(CH2)n-NRa-CO-Rb' groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2)n-CO-NRaRb groups, wherein n, p, x and y are each independently integers from 0 to 3, q is 0 or 1, Rf, Rg, Rh, Ri, Rj and Rk independently represent hydrogen atoms or halogen atoms, Rb' is selected from the group consisting of methylsulphonyl groups, C1-4 alkyl groups, C1-4 hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups; Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 alkyl groups, C1-4 hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups, or Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by - NHR' wherein R' represents a hydrogen atom or a 61-4 carboxyalkyl group.